Arca
Skip to content
Tools
Tools

DLL3: Delta-like protein 3

Inhibits primary neurogenesis.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on DLL3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Antibody-drug conjugate 1

Approved1

  • Tarlatamab

Phase 31

  • Rovalpituzumab tesirine

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      TarlatamabApprovedAmgenAntibodyBinding agentDelta-like protein 3 binding agent38
      Rovalpituzumab tesirinePhase 3AbbVieAntibody-drug conjugateBinding agentDelta-like protein 3 binding agent0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerTarlatamabPhase 2Not yet recruitingAbbVieOct 26, 2026
      Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung CancerTarlatamab—Active, not recruitingRuijin HospitalOct 21, 2026
      Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusTarlatamabPhase 2RecruitingAIO-Studien-gGmbHSep 4, 2026
      Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)TarlatamabPhase 1Not yet recruitingVall d'Hebron Institute of OncologyAug 26, 2026
      Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept StudyTarlatamabPhase 2Not yet recruitingUniversity Hospital, Strasbourg, FranceAug 26, 2026
      Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)TarlatamabPhase 3RecruitingAmgenAug 21, 2026
      A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)TarlatamabPhase 2Not yet recruitingUniversity of CologneJul 13, 2026
      Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerTarlatamabPhase 3Not yet recruitingPrECOG, LLC.Jun 9, 2026

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Spondylocostal dysostosis 1, autosomal recessive
      0.72
      Small cell lung carcinoma
      0.59
      Autosomal recessive spondylocostal dysostosis
      0.53
      Neurodegenerative disease
      0.53
      Cancer
      0.46
      Neoplasm
      0.42
      Hereditary disease
      0.42
      Spondylocostal dysostosis
      0.38
      Leukodystrophy and acquired microcephaly with or without dystonia;
      0.34
      Rib fusion
      0.34
      Hemivertebrae
      0.34
      Neuroendocrine carcinoma
      0.32

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630888, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9NYJ7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.